Compare The Vita Coco Company Inc (COCO) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Vita Coco Company Inc vs Danaher Corporation — how do they compare? The Vita Coco Company Inc trades at $65.5 (market cap $3.73B), while Danaher Corporation trades at $206.9 (market cap $145.83B). The key difference: Danaher Corporation is far larger — about 39.1× The Vita Coco Company Inc's market cap, and Danaher Corporation pays a 0.77% dividend while The Vita Coco Company Inc pays none. Which is the better fit depends on your goals.
| COCO | DHR | |
|---|---|---|
Market Cap | $3.73B | $145.83B |
Sector | Technology | Health |
52-Week High | $84.02 | $242.05 |
52-Week Low | $32.37 | $161.91 |
Enterprise Value | $3.47B | $168.04B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COCO trades at $64.96, up 3.47% on the day, with strong earnings beats in Q1 and Q2 2026 driving momentum. The stock shows a bearish technical signal but bullish oscillators, with support near $62 and resistance at $65. Recent Q2 results featured 28% revenue growth and raised 2026 guidance, supported by the Copra acquisition and international expansion.
Outlook is positive with 60% analyst buy ratings and an $80.67 price target, though high valuation multiples and cost pressures pose risks. Growth catalysts include brand demand and market share gains, while investor sentiment is bolstered by defensive stock attributes amid economic uncertainty.
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
